SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilBigKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 10/23/2017 5:41:10 PM - Followers: 725 - Board type: Free - Posts Today: 45

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

SureTrader
Interactive Brokers Advertisement
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Notice of Effectiveness (effect) 09/22/2017 06:02:17 AM
IPIX News: Securities Registration Statement (simplified Form) (s-3) 09/11/2017 12:47:10 PM
IPIX News: Annual Report (10-k) 09/11/2017 06:04:38 AM
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 09/11/2017 06:04:37 AM
IPIX News: Statement of Changes in Beneficial Ownership (4) 09/06/2017 06:27:18 PM
PostSubject
#200759  Sticky Note IPIX is looking for partnerships after P2's. petemantx 10/19/17 10:14:05 PM
#200267  Sticky Note Cellceutix Reports Very Encouraging Interim Analysis of Phase scottsmith 10/16/17 07:19:09 PM
#200091  Sticky Note IPIX Clinical Trial Timelines sox040713 10/14/17 08:13:18 PM
#198202  Sticky Note $IPIX - Innovation Pharmaceuticals Stock May Be A TheHound 09/26/17 02:43:47 PM
#197995  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents sox040713 09/24/17 05:24:48 PM
#191428  Sticky Note $IPIX - Innovation Pharmaceuticals Stock May Be A LilBigKahuna 07/23/17 12:25:32 AM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#199193   I would take $5 MXAMDUD 10/05/17 03:50:18 PM
#199192   Not a "POS". It's a clinical stage biotech DaysOnTheBeach 10/05/17 03:50:09 PM
#199191   POS? yes Point of Sale. We will all septmike09 10/05/17 03:48:43 PM
#199189  Restored This POS just went red on the day MXAMDUD 10/05/17 03:25:22 PM
#199187   Getting close folks. Big news coming soon. septmike09 10/05/17 03:14:05 PM
#199184   The people have spoken and I will remove scottsmith 10/05/17 02:22:18 PM
#199181   It's not. It's B.S. It needs to be removed. septmike09 10/05/17 02:17:23 PM
#199180   I don't think this post is factual regarding DoubleJ23 10/05/17 02:16:30 PM
#199176   BULLSHIT ! Most Relevant and Interesting ! WOW WILD_4_IPIX 10/05/17 01:56:39 PM
#199174   What would you like me to sticky? scottsmith 10/05/17 01:45:54 PM
#199173   Stickys should be reserved for important information about 58nout 10/05/17 01:43:30 PM
#199165   Why do we have blatantly false information stickied 58nout 10/05/17 01:13:28 PM
#199164   Obviously the statement in question isn't true and loanranger 10/05/17 01:03:48 PM
#199163   And you wouldn't blame Leo for using funds G Bert 10/05/17 01:01:18 PM
#199162   the short interest folly could be put to MXAMDUD 10/05/17 12:40:37 PM
#199161   Short interest and sellers are a constant topic scottsmith 10/05/17 12:37:27 PM
#199160   about to go red on the day. MXAMDUD 10/05/17 12:31:52 PM
#199159   REGN to buy IPIX??? its halted. MXAMDUD 10/05/17 12:06:37 PM
#199158   I just glanced at a chart. Great news. TheDane 10/05/17 12:02:34 PM
#199157   this POS can't even hold .72. pathetic MXAMDUD 10/05/17 11:56:48 AM
#199156  Restored how did this get stickied?????? 58nout 10/05/17 11:56:03 AM
#199155   LBK is spot on here. Anyone who baytdr 10/05/17 11:34:25 AM
#199154   Well said. Savvy management and outstanding science AlanC 10/05/17 11:33:48 AM
#199153   Yep and here's the most frustrating thing for 58nout 10/05/17 11:20:44 AM
#199152   Huh? Its not 10s of millions of short LilBigKahuna 10/05/17 11:04:11 AM
#199151   If they can sell then you certainly should groton68 10/05/17 10:59:49 AM
#199149   That’s because this is an investment stock and LilBigKahuna 10/05/17 10:53:25 AM
#199148   Done. Eom scottsmith 10/05/17 10:46:23 AM
#199147   Sorry this post doesn't add up. The scottsmith 10/05/17 10:41:21 AM
#199146   Unpin Nerby's prurisol inquiry. No validation, might be jav0033 10/05/17 10:33:30 AM
#199145   yeah - an ask that continually gets lowered. MXAMDUD 10/05/17 10:20:15 AM
#199144   Of course you can’t sell a low volume LilBigKahuna 10/05/17 10:15:44 AM
#199143   its impossible to sell MXAMDUD 10/05/17 09:59:41 AM
#199142   What evidence do you have to support that? groton68 10/05/17 09:58:52 AM
#199141   and right on cue - they move the MXAMDUD 10/05/17 09:51:37 AM
#199140   this stock is so pathetic, I can't even MXAMDUD 10/05/17 09:37:56 AM
#199139   Does it frrol 10/05/17 09:34:17 AM
#199138   Terrific post! The logic and simplicity sums up farrell90 10/05/17 09:11:42 AM
#199137   Regardless of who pretends to know what I bradfordbros 10/05/17 09:09:08 AM
#199136   The twice monthly FINRA report says There are LilBigKahuna 10/05/17 09:03:38 AM
#199135   That is partially true. But if you scottsmith 10/05/17 08:58:26 AM
#199134   These negotiations IMO will be extremely complicated based DaubersUP 10/05/17 08:48:56 AM
#199133   It's more a "hope you're right" type of bradfordbros 10/05/17 08:46:32 AM
#199132   "Coulds" and "ifs" on cusip and name changes AlanC 10/05/17 08:35:57 AM
#199131   When you buy a share of XYZ, there frrol 10/05/17 08:32:02 AM
#199128   EXCELLENT Cyber....THANKS ! WILD_4_IPIX 10/05/17 07:54:54 AM
#199127   The current Prurisol Phase 2b trial will be georgejjl 10/05/17 07:08:35 AM
#199126   Innovation has successfully completed a Phase 2 clinical georgejjl 10/05/17 06:53:01 AM
#199125   Thanks Cyber. 58nout 10/05/17 06:43:31 AM
#199123   Mgmt has been talking about BP for more Amatuer17 10/05/17 05:32:20 AM
PostSubject